Over the past month Karolinska Development has reported a series of positive outcomes for several of its portfolio companies. The most important in terms of impact on our valuation are the encouraging results from Umecrine Cognition’s Phase Ib study and, to a lesser extent, the successful flotation of BioArctic. A number of further value inflection points, across many of the portfolio companies, are expected over the next 12-18 months. Updating our DCF-based model sees our valuation rise from SEK566m (equivalent to SEK8.92 per share) to SEK1,042m (SEK16.44 per share)
26 Oct 2017
Positive news flow drives valuation uplift
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Positive news flow drives valuation uplift
Karolinska Development AB Class B (0P3C:LON) | 0 0 5.4% | Mkt Cap: 369.6m
- Published:
26 Oct 2017 -
Author:
Mick Cooper PhD -
Pages:
6
Over the past month Karolinska Development has reported a series of positive outcomes for several of its portfolio companies. The most important in terms of impact on our valuation are the encouraging results from Umecrine Cognition’s Phase Ib study and, to a lesser extent, the successful flotation of BioArctic. A number of further value inflection points, across many of the portfolio companies, are expected over the next 12-18 months. Updating our DCF-based model sees our valuation rise from SEK566m (equivalent to SEK8.92 per share) to SEK1,042m (SEK16.44 per share)